FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eva Hellström-Lindberg

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Concepts & Ideas

Treatment Outcome

Procedures

Remission Induction

Co-author Network

Publications

TOP 3
Maryam Nikpour; E Papaemmanuil; C Scharenberg; J Stephen Wainscoat; I Vedin; K Högstrand; M Jansson; M Karimi; Anquan Liu; T Mortera-Blanco; Jacqueline Boultwood; P Campbell; Mario Cazzola; S Conte; M Fernandez-Mercado; V Giai; Alf Grandien; Eva Hellström-Lindberg
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts.
Marianne B Treppendahl; Paul Cloos; Eva Hellström-Lindberg; Lars Möllgård; Kirsten Grønbaek
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q.
Leonie Saft; Elisabeth Berg; Elisabet Björklund; Eva Hellström-Lindberg; Anna Porwit
Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eva Hellström-Lindberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Maryam Nikpour; E Papaemmanuil; C Scharenberg; J Stephen Wainscoat; I Vedin; K Högstrand; M Jansson; M Karimi; Anquan Liu; T Mortera-Blanco; Jacqueline Boultwood; P Campbell; Mario Cazzola; S Conte; M Fernandez-Mercado; V Giai; Alf Grandien; Eva Hellström-Lindberg
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts.
Leukemia 2013;27(4):889-96.
2013: Marianne B Treppendahl; Paul Cloos; Eva Hellström-Lindberg; Lars Möllgård; Kirsten Grønbaek
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q.
European journal of haematology 2013;90(3):259-60.
2013: Leonie Saft; Elisabeth Berg; Elisabet Björklund; Eva Hellström-Lindberg; Anna Porwit
Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes.
Leukemia research 2013;37(3):266-73.
2012: Thom Duyvené de Wit; Gareth Evans-Jones; Eva Hellström-Lindberg; Ulrich Jäger; Carin Smand
H-Net, the European Network for Harmonization of Training in Hematology, and its policy.
Haematologica 2012;97(12):1776-8.
2012: Gert Ossenkoppele; Gareth Evans-Jones; Eva Hellström-Lindberg; Ulrich Jaeger
Towards a joint definition of European hematology.
Haematologica 2012;97(5):636-7.
2012: Gudrun Göhring; Eva Hellström-Lindberg; W Hofmann; Hans Kreipe; K Lange; M Morgan; K V Nielsen; L Roy; Guntram Büsche; Aristoteles Giagounidis; Brigitte Schlegelberger
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Leukemia 2012;26(2):356-8.
2011: Luca Malcovati; Laura J Mudie; Elli Papaemmanuil; Cristiana Pascutto; Michael R Stratton; S Tauro; Erica Travaglino; James S Wainscoat; Ilaria Ambaglio; Jacqueline Boultwood; David T Bowen; Peter J Campbell; Mario Cazzola; Simona Conte; Matteo C Da Vià; Matteo G Della Porta; P Andrew Futreal; Anna Gallì; Anna L Godfrey; Michael J Groves; Eva Hellström-Lindberg; Jonathan Hinton; Ann Hyslop; Norene Keenan
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Blood 2011;118(24):6239-46.
2011: Pierre Fenaux; John Francis; Tommy Fu; Arnold Ganser; Aristoteles Giagounidis; Agnes Guerci-Bresler; Eva Hellström-Lindberg; Robert Knight; Michael Lübbert; Moshe Mittelman; Ghulam Mufti; Petra Muus; Lars Nilsson; Uwe Platzbecker; Bruno Quesnel; Guillermo Sanz; Brigitte Schlegelberger; Dominik Selleslag; Peter Te Boekhorst; Carlo Aul; Odile Beyne-Rauzy; David Bowen; Mario Cazzola; Consuelo Del Cañizo
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Blood 2011;118(14):3765-76.
2011: Andrea Pellagatti; Janet Perry; Paresh Vyas; James S Wainscoat; Mario Cazzola; Matteo Della Porta; Aristoteles Giagounidis; Eva Hellström-Lindberg; Martin Jädersten; Sally Killick; Luca Malcovati; Jacqueline Boultwood
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
British journal of haematology 2011;155(2):272-4.
2011: Herman Nilsson-Ehle; Anna Olsson; Jan Samuelsson; Mette Skov-Holm; Jonas Wallvik; Petar Antunovic; Jan Astermark; Gunnar Birgegård; Lena M Engström; Hege Garelius; Nina Gulbrandsen; Lars Kjeldsen; Lars Nilsson; Eva Hellström-Lindberg
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
European journal of haematology 2011;87(3):244-52.
2011: Lewis R Silverman; Pierre Fenaux; Norbert Gattermann; Steven D Gore; Eva Hellström-Lindberg; Alan F List; Ghulam J Mufti; Valeria Santini; Guillermo Sanz; John F Seymour
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
Cancer 2011;117(12):2697-702.
2011: Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):1971-9.
2011: Gudrun Göhring; Aristoteles Giagounidis; Guntram Büsche; Winfried Hofmann; Hans H Kreipe; Pierre Fenaux; Eva Hellström-Lindberg; Brigitte Schlegelberger
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
Haematologica 2011;96(2):319-22.
2010: John F Seymour; Pierre Fenaux; Lewis R Silverman; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Alan F List; Steven D Gore; Jay Backstrom; David McKenzie; C L Beach
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.
Critical reviews in oncology/hematology 2010;76(3):218-27.
2010: Pierre Fenaux; David Bowen; Norbert Gattermann; Eva Hellström-Lindberg; Wolf-Karsten Hofmann; Michael Pfeilstöcker; Guillermo Sanz; Valeria Santini
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
Leukemia research 2010;34(11):1410-6.
2010: Theo de Witte; Anne Hagemeijer; Stefan Suciu; Amin Belhabri; Michel Delforge; Guido Kobbe; Dominik Selleslag; Harry C Schouten; Augustin Ferrant; Harald Biersack; Sergio Amadori; Petra Muus; Joop H Jansen; Eva Hellström-Lindberg; Tibor J Kovacsovics; Pierre W Wijermans; Gert Ossenkoppele; Alois Gratwohl; Jean-Pierre Marie; Roel Willemze
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.
Haematologica 2010;95(10):1754-61.
2010: Ramin Tehranchi; Petter S Woll; Kristina Anderson; Natalija Buza-Vidas; Takuo Mizukami; Adam J Mead; Ingbritt Astrand-Grundström; Bodil Strömbeck; Andrea Horvat; Helen Ferry; Rakesh Singh Dhanda; Robert Hast; Tobias Rydén; Paresh Vyas; Gudrun Göhring; Brigitte Schlegelberger; Bertil Johansson; Eva Hellström-Lindberg; Alan List; Lars Nilsson; Sten Eirik W Jacobsen
Persistent malignant stem cells in del(5q) myelodysplasia in remission.
The New England journal of medicine 2010;363(11):1025-37.
2010: Michael Grövdal; Mohsen Karimi; Rasheed Khan; Anni Aggerholm; Petar Antunovic; Jan Astermark; Per Bernell; Lena-Maria Engström; Lars Kjeldsen; Olle Linder; Lars Nilsson; Anna Olsson; Mette S Holm; Jon Magnus Tangen; Jonas Wallvik; Gunnar Oberg; Peter Hokland; Sten E Jacobsen; Anna Porwit; Eva Hellström-Lindberg
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
British journal of haematology 2010;150(3):293-302.
2010: Valeria Santini; Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Lewis R Silverman; Alan List; Steven D Gore; John F Seymour; Jay Backstrom; Charles L Beach
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
European journal of haematology 2010;85(2):130-8.
2010: Eva Hellström-Lindberg
Erythropoiesis-stimulating agents in myelodysplastic syndromes.
Leukemia & lymphoma 2010;51(7):1155-6.
2010: Maryam Nikpour; Andrea Pellagatti; Anquan Liu; Mohsen Karimi; Luca Malcovati; Vladimir Gogvadze; Ann-Mari Forsblom; james wainscoat; Mario Cazzola; Boris Zhivotovsky; Alf Grandien; Jacqueline Boultwood; Eva Hellström-Lindberg
Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
British journal of haematology 2010;149(6):844-54.
2010: S Deneberg; M Grövdal; M Karimi; M Jansson; H Nahi; A Corbacioglu; V Gaidzik; Konstanze Döhner; Christer Paul; T J Ekström; Eva Hellström-Lindberg; S Lehmann
Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.
Leukemia 2010;24(5):932-41.
2010: Martin Jädersten; Eva Hellström-Lindberg
New clues to the molecular pathogenesis of myelodysplastic syndromes.
Experimental cell research 2010;316(8):1390-6.
2010: Andrea Pellagatti; Mario Cazzola; Aristoteles Giagounidis; J Perry; Luca Malcovati; Matteo Della Porta; Martin Jädersten; Sally Killick; Amit Verma; C J Norbury; Eva Hellström-Lindberg; james wainscoat; Jacqueline Boultwood
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
Leukemia 2010;24(4):756-64.
2010: Pierre Fenaux; Norbert Gattermann; John F Seymour; Eva Hellström-Lindberg; Ghulam J Mufti; Ulrich Duehrsen; Steven D Gore; Fernando Ramos; Odile Beyne-Rauzy; Alan List; David McKenzie; Jay Backstrom; Charles L Beach
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
British journal of haematology 2010;149(2):244-9.
2010: Gudrun Göhring; Aristoteles Giagounidis; Guntram Büsche; Hans H Kreipe; Martin Zimmermann; Eva Hellström-Lindberg; Carlo Aul; Brigitte Schlegelberger
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Annals of hematology 2010;89(4):365-74.
2010: Eva Hellström-Lindberg
Significance of JAK2 and TET2 mutations in myelodysplastic syndromes.
Blood reviews 2010;24(2):83-90.
2010: Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven D Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):562-9.
2009: Martin Jädersten; Leonie Saft; Andrea Pellagatti; Gudrun Göhring; james wainscoat; Jacqueline Boultwood; Anna Porwit; Brigitte Schlegelberger; Eva Hellström-Lindberg
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Haematologica 2009;94(12):1762-6.
2009: Luca Malcovati; Matteo G Della Porta; Daniela Pietra; Emanuela Boveri; Andrea Pellagatti; Anna Gallì; Erica Travaglino; Angela Brisci; Elisa Rumi; Francesco Passamonti; Rosangela Invernizzi; Laura Cremonesi; Jacqueline Boultwood; james wainscoat; Eva Hellström-Lindberg; Mario Cazzola
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Blood 2009;114(17):3538-45.
2009: Björn Löfström; Carin Backlin; Christer Sundström; Eva Hellström-Lindberg; Anders Ekbom; Ingrid E Lundberg
Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers.
Rheumatology (Oxford, England) 2009;48(10):1222-6.
2009: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
Blood 2009;114(5):937-51.
2009: Andrea Pellagatti; Teresa Marafioti; Jennifer C Paterson; Luca Malcovati; Matteo Della Porta; Martin Jädersten; Beena Pushkaran; Tracy I George; Daniel A Arber; Sally Killick; Aristoteles Giagounidis; Eva Hellström-Lindberg; Mario Cazzola; james wainscoat; Jacqueline Boultwood
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
British journal of haematology 2009;146(1):86-90.
2008: Ghulam J Mufti; john bennett; Jean Goasguen; Barbara J Bain; Irith Baumann; Richard Brunning; Mario Cazzola; Pierre Fenaux; Ulrich Germing; Eva Hellström-Lindberg; Itsuro Jinnai; Atsushi Manabe; Akira Matsuda; Charlotte M Niemeyer; Guillermo Sanz; Masao Tomonaga; Teresa Vallespi; Ayami Yoshimi
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.
Haematologica 2008;93(11):1712-7.
2008: Martin Jädersten; Luca Malcovati; Ingunn Dybedal; Matteo Giovanni Della Porta; Rosangela Invernizzi; Scott M Montgomery; Cristiana Pascutto; Anna Porwit; Mario Cazzola; Eva Hellström-Lindberg
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3607-13.
2008: Andrea Pellagatti; Eva Hellström-Lindberg; Aristoteles Giagounidis; Janet Perry; Luca Malcovati; Matteo Della Porta; Martin Jädersten; Sally Killick; Carrie Fidler; Mario Cazzola; james wainscoat; Jacqueline Boultwood
Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
British journal of haematology 2008;142(1):57-64.
2008: Matti S Aapro; Gunnar Birgegård; Carsten Bokemeyer; Paul Cornes; Jan Foubert; Pere Gascon; John Glaspy; Eva Hellström-Lindberg; Hartmut Link; Heinz Ludwig; Anders Osterborg; Lazzaro Repetto; Pierre Soubeyran
Erythropoietins should be used according to guidelines.
The lancet oncology 2008;9(5):412-3.
2008: Eva Hellström-Lindberg; Luca Malcovati
Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
Blood reviews 2008;22(2):75-91.
2008: Rasheed Khan; Jan Schmidt-Mende; Mohsen Karimi; Vladimir Gogvadze; Moustapha Hassan; Tomas J Ekström; Boris Zhivotovsky; Eva Hellström-Lindberg
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells.
Experimental hematology 2008;36(2):149-57.
2008: Pierre Fenaux; Norbert Gattermann; Eva Hellström-Lindberg; D McKenzie; V Santini; G Sanz; L Zimmerman; C L Beach; Steven D Gore; A F List; G J Mufti; J F Seymour; J Backstrom; L B Silverman
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update.
Ecancermedicalscience 2008;2():121.
2008: L R Silverman; Steven D Gore; A F List; G J Mufti; J F Seymour; J Backstrom; Pierre Fenaux; Norbert Gattermann; Eva Hellström-Lindberg; D McKenzie; V Santini; G Sanz; C L Beach
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.
Ecancermedicalscience 2008;2():118.
2008: Jacqueline Boultwood; Andrea Pellagatti; Maryam Nikpour; Beena Pushkaran; Carrie Fidler; Helen Cattan; Timothy J Littlewood; Luca Malcovati; Matteo Della Porta; Martin Jädersten; Sally Killick; Aristoteles Giagounidis; David Bowen; Eva Hellström-Lindberg; Mario Cazzola; james wainscoat
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.
PloS one 2008;3(4):e1970.
2008: Eva Hellström-Lindberg; Luca Malcovati
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
Seminars in hematology 2008;45(1):14-22.
2007: Michael Grövdal; Rasheed Khan; Anni Aggerholm; Petar Antunovic; Jan Astermark; Per Bernell; Lena-Maria Engström; Lars Kjeldsen; Olle Linder; Lars Nilsson; Anna Olsson; Jonas Wallvik; Jon Magnus Tangen; Gunnar Oberg; Sten Eirik W Jacobsen; Peter Hokland; Anna Porwit; Eva Hellström-Lindberg
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(23):7107-12.
2007: Jacqueline Boultwood; Andrea Pellagatti; Helen Cattan; Charles H Lawrie; Aristoteles Giagounidis; Luca Malcovati; Matteo Della Porta; Martin Jädersten; Sally Killick; Carrie Fidler; Mario Cazzola; Eva Hellström-Lindberg; james wainscoat
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
British journal of haematology 2007;139(4):578-89.
2007: Lars Nilsson; Patrik Edén; Eleonor Olsson; Robert Månsson; Ingbritt Astrand-Grundström; Bodil Strömbeck; Kim Theilgaard-Mönch; Kristina Anderson; Robert Hast; Eva Hellström-Lindberg; Jan Samuelsson; Gösta Bergh; Claus Nerlov; Bertil Johansson; Mikael Sigvardsson; Ake Borg; Sten Eirik W Jacobsen
The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
Blood 2007;110(8):3005-14.
2007: Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; james wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(27):11406-11.
2007: Anders I Seldén; Christine Karlson-Stiber; Carin Norberg; Eva Hellström-Lindberg
Cobalt release from glazed earthenware: Observations in a case of lead poisoning.
Environmental toxicology and pharmacology 2007;23(1):129-31.
2006: Thomas F Goss; Agota Szende; Caroline Schaefer; P Jane Totten; Robert Knight; Martin Jädersten; Eva Hellström-Lindberg; Alan F List
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Cancer control : journal of the Moffitt Cancer Center 2006;13 Suppl():17-25.
2006: Lars Göran Lundberg; Eva Hellström-Lindberg; Lena Kanter-Lewensohn; Richard Lerner; Jan Palmblad
Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Leukemia research 2006;30(3):247-53.
2006: Eva Hellström-Lindberg; Andreas Björklund; Christine Karlson-Stiber; Pauline Harper; Anders I Seldén
Lead poisoning from souvenir earthenware.
International archives of occupational and environmental health 2006;79(2):165-8.
2006: Rasheed Khan; Anni Aggerholm; Peter Hokland; Moustapha Hassan; Eva Hellström-Lindberg
A pharmacodynamic study of 5-azacytidine in the P39 cell line.
Experimental hematology 2006;34(1):35-43.
2006: Gunnar Juliusson; Rolf Billström; A Gruber; Eva Hellström-Lindberg; M Höglunds; Karin Karlsson; Dick Stockelberg; Ake Wahlin; Maria Aström; C Arnesson; U Brunell-Abrahamsson; J Carstensen; E Fredriksson; E Holmberg; K Nordenskjöld; F Wiklund
Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
Leukemia 2006;20(1):42-7.
2006: Jan Schmidt-Mende; Vladimir Gogvadze; Eva Hellström-Lindberg; Boris Zhivotovsky
Early mitochondrial alterations in ATRA-induced cell death.
Cell death and differentiation 2006;13(1):119-28.
2005: Ramin Tehranchi; Bengt Fadeel; Jan Schmidt-Mende; Ann-Mari Forsblom; Emma Emanuelsson; Martin Jadersten; Birger Christensson; Robert Hast; Robert B Howe; Jan Samuelsson; Boris Zhivotovsky; Eva Hellström-Lindberg
Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6291-9.
2005: Martin Jädersten; Scott M Montgomery; Ingunn Dybedal; Anna Porwit-MacDonald; Eva Hellström-Lindberg
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.
Blood 2005;106(3):803-11.
2005: Ramin Tehranchi; Rosangela Invernizzi; Alf Grandien; Boris Zhivotovsky; Bengt Fadeel; Ann-Mari Forsblom; Erica Travaglino; Jan Samuelsson; Robert Hast; Lars Nilsson; Mario Cazzola; Rolf Wibom; Eva Hellström-Lindberg
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.
Blood 2005;106(1):247-53.
2005: Eva Hellström-Lindberg
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2005;():161-6.
2005: Nicolaus Kröger; Ronald Brand; Anja van Biezen; D Bron; D Blaise; Eva Hellström-Lindberg; Gösta Gahrton; R Powles; T Littlewood; Bernard Chapuis; Axel Zander; V Koza; Dietger Niederwieser; Theo de Witte
Stem cell transplantation from identical twins in patients with myelodysplastic syndromes.
Bone marrow transplantation 2005;35(1):37-43.
2004: Therese Ljung; Rune Bäck; Eva Hellström-Lindberg
Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Haematologica 2004;89(12):1446-53.
2004: Göran Carlsson; Andrew A G Aprikyan; Ramin Tehranchi; David C Dale; Anna Porwit; Eva Hellström-Lindberg; Jan Palmblad; Jan-Inge Henter; Bengt Fadeel
Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells.
Blood 2004;103(9):3355-61.
2004: Robert B Howe; Anna Porwit-MacDonald; Robert Wanat; Ramin Tehranchi; Eva Hellström-Lindberg
The WHO classification of MDS does make a difference.
Blood 2004;103(9):3265-70.
2003: Robert Hast; Eva Hellström-Lindberg; L Ohm; Magnus Björkholm; Fredrik Celsing; Inger Marie S Dahl; Ingunn Dybedal; Gösta Gahrton; G Lindberg; Richard Lerner; Olle Linder; Eva Löfvenberg; H Nilsson-Ehle; Christer Paul; Jan Samuelsson; Jon Magnus Tangen; Ulf Tidefelt; Ingemar Turesson; Ake Wahlin; Jonas Wallvik; Ingemar Winquist; Gunnar Oberg; Per Bernell
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Leukemia 2003;17(9):1827-33.
2003: Eva Hellström-Lindberg
Approach to anemia associated with myelodysplastic syndromes.
Current hematology reports 2003;2(2):122-9.
2003: Eva Hellström-Lindberg; Nina Gulbrandsen; Greger Lindberg; Tomas Ahlgren; Inger Marie S Dahl; Ingunn Dybedal; Gunnar Grimfors; Eva Hesse-Sundin; Martin Hjorth; Lena Kanter-Lewensohn; Olle Linder; Michaela Luthman; Eva Löfvenberg; Gunnar Oberg; Anna Porwit-MacDonald; Anders Rådlund; Jan Samuelsson; Jon Magnus Tangen; Ingemar Winquist; Finn Wisloff
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
British journal of haematology 2003;120(6):1037-46.
2002: Zuzana Hassan; Eva Hellström-Lindberg; S Alsadi; M Edgren; H Hägglund; Moustapha Hassan
The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.
Bone marrow transplantation 2002;30(3):141-7.
2002: Lars Nilsson; Ingbritt Astrand-Grundström; Kristina Anderson; Ingrid Arvidsson; Peter Hokland; David Bryder; Lars Kjeldsen; Bertil Johansson; Eva Hellström-Lindberg; Robert Hast; Sten Eirik W Jacobsen
Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
Blood 2002;100(1):259-67.
2002: Eva Hellström-Lindberg
Sixth International Symposium on Myelodysplastic Syndromes, Stockholm, June 14-17, 2001.
International journal of hematology 2002;75(2):209-12.
2001: Z Hassan; M Hassan; Eva Hellström-Lindberg
The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro.
Leukemia 2001;15(8):1240-7.
2001: Jan Schmidt-Mende; Ramin Tehranchi; Ann-Mari Forsblom; Bertrand Joseph; Birger Christensson; Bengt Fadeel; Boris Zhivotovsky; Eva Hellström-Lindberg
Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts.
Leukemia 2001;15(5):742-51.
2001: Eva Hellström-Lindberg; Jan Schmidt-Mende; Ann-Mari Forsblom; Birger Christensson; Bengt Fadeel; Boris Zhivotovsky
Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases.
British journal of haematology 2001;112(3):714-26.
2001: J Lindahl; Eva Kimby; Bo Björkstrand; Birger Christensson; Eva Hellström-Lindberg
High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD.
Leukemia research 2001;25(3):267-70.
2000: Jan Schmidt-Mende; Eva Hellström-Lindberg; Bertrand Joseph; Boris Zhivotovsky
Freezing induces artificial cleavage of apoptosis-related proteins in human bone marrow cells.
Journal of immunological methods 2000;245(1-2):91-4.
2000: Lars Nilsson; Ingbritt Astrand-Grundström; Ingrid Arvidsson; Björn Jacobsson; Eva Hellström-Lindberg; Robert Hast; Sten Eirik W Jacobsen
Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.
Blood 2000;96(6):2012-21.
1999: Eva Hellström-Lindberg
Treatment of adult myelodysplastic syndromes.
International journal of hematology 1999;70(3):141-54.
1999: Zuzana Hassan; Bengt Fadeel; Boris Zhivotovsky; Eva Hellström-Lindberg
Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39.
Experimental hematology 1999;27(8):1322-9.
1999: Eva Hellström-Lindberg; Lena Kanter-Lewensohn; J Nichol; Ake Ost
Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway.
British journal of haematology 1999;105(4):966-73.
1999: Bengt Fadeel; Z Hassan; Eva Hellström-Lindberg; Jan-Inge Henter; S Orrenius; Boris Zhivotovsky
Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells.
Leukemia 1999;13(5):719-28.
1999: G Nordesjö-Haglund; B Lönnqvist; G Lindberg; Eva Hellström-Lindberg
Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation.
Lancet 1999;353(9155):846.
1998: Eva Hellström-Lindberg; Tomas Ahlgren; Y Beguin; M Carlsson; Jan Carneskog; Inger Marie S Dahl; Ingunn Dybedal; Gunnar Grimfors; Lena Kanter-Lewensohn; Olle Linder; Michaela Luthman; Eva Löfvenberg; H Nilsson-Ehle; Jan Samuelsson; Jon Magnus Tangen; I Winqvist; Gunnar Oberg; Anders Osterborg; Ake Ost
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
Blood 1998;92(1):68-75.
1997: Eva Hellström-Lindberg; R Negrin; R Stein; S Krantz; G Lindberg; J Vardiman; Ake Ost; P Greenberg
Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
British journal of haematology 1997;99(2):344-51.
1997: Eva Hellström-Lindberg; Lena Kanter-Lewensohn; Ake Ost
Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin.
Leukemia research 1997;21(5):415-25.
1996: Lena Kanter-Lewensohn; Eva Hellström-Lindberg; Y Kock; A Elmhorn-Rosenborg; Ake Ost
Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
European journal of haematology 1996;56(3):124-9.
1995: S Widell; Eva Hellström-Lindberg; Y Kock; M Lindberg; Ake Ost; Robert Hast
Peripheral blood neutrophil morphology reflects bone marrow dysplasia in myelodysplastic syndromes.
American journal of hematology 1995;49(2):115-20.
1995: Eva Hellström-Lindberg
Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.
British journal of haematology 1995;89(1):67-71.
1994: Eva Hellström-Lindberg; Robert Hast; A Rådlund; Ake Ost
[Incidence of myelodysplastic syndrome is increasing. Careful diagnosis is necessary for choice of the treatment].
Läkartidningen 1994;91(46):4253-8.
1994: Eva Hellström-Lindberg; K H Robèrt; Gösta Gahrton; G Lindberg; A M Forsblom; Y Kock; Ake Ost
Low-dose ara-C in myelodysplastic syndromes (MDS) and acute leukemia following MDS: proposal for a predictive model.
Leukemia & lymphoma 1994;12(5-6):343-51.
1993: Eva Hellström-Lindberg; Gunnar Birgegård; M Carlsson; Jan Carneskog; Inger Marie S Dahl; I Dybedal; Gunnar Grimfors; K Merk; Jon Magnus Tangen; I Winqvist
A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.
Leukemia & lymphoma 1993;11(3-4):221-8.
1992: Eva Hellström-Lindberg; K H Robèrt; Gösta Gahrton; G Lindberg; A M Forsblom; Y Kock; Ake Ost
A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia.
British journal of haematology 1992;81(4):503-11.
1992: Eva Hellström-Lindberg; K H Robèrt; B Ahnsén; A Elmhorn-Rosenborg; Y Kock; Ake Ost
In vitro suspension culture reactions to 1,25 dihydroxyvitamin D3 in relation to bone marrow morphology and prognosis in patients with myelodysplastic syndromes.
Leukemia research 1992;16(5):529-35.